<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-25T02:22:52Z</responseDate><request verb="GetRecord" identifier="oai:univendspace.univen.ac.za:11602/3190" metadataPrefix="dim">https://univendspace.univen.ac.za/server/oai/request</request><GetRecord><record><header><identifier>oai:univendspace.univen.ac.za:11602/3190</identifier><datestamp>2026-06-18T01:00:48Z</datestamp><setSpec>com_11602_1924</setSpec><setSpec>com_11602_1914</setSpec><setSpec>com_11602_1897</setSpec><setSpec>com_11602_737</setSpec><setSpec>col_11602_2142</setSpec><setSpec>col_11602_738</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Tshifaro, Bongani Steven</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-06-17T14:12:21Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2026-06-17T14:12:21Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2026-05-19</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="citation" lang="en_ZA">Tshifaro, B.S. 2026. Synthesis of sulfonylthioureas as anti-diabetic drugs. . . </dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://univendspace.univen.ac.za/handle/11602/3190</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="vancouvercitation" lang="en_ZA">Tshifaro BS. Synthesis of sulfonylthioureas as anti-diabetic drugs. []. , 2026 [cited yyyy month dd]. Available from: </dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="apacitation" lang="en_ZA">Tshifaro, B. S. (2026). &amp;lt;i&amp;gt;Synthesis of sulfonylthioureas as anti-diabetic drugs&amp;lt;/i&amp;gt;. (). . Retrieved from </dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="chicagocitation" lang="en_ZA">Tshifaro, Bongani Steven. &amp;lt;i&amp;gt;&amp;quot;Synthesis of sulfonylthioureas as anti-diabetic drugs.&amp;quot;&amp;lt;/i&amp;gt; ., , 2026. </dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="ris" lang="en_ZA">&#xd;
TY  - Dissertation&#xd;
AU  - Tshifaro, Bongani Steven&#xd;
AB  - This dissertation discussed the synthesis, cytotoxicity and alpha-glucosidase inhibition of sulfonamides and novel sulfonylthiourea compounds. Three series of novel sulfonylthiourea [benzamido-benzenesulfonylthiourea (28a-28d), pyrrolidino-benzenesulfonylthiourea (33a-33c) and acetamido-benzenesulfonylthiourea (26a-26k) were successfully synthesized in moderate yields to excellent yields. Four novel benzamido-benzenesulfonylthiourea 28a, 28b, 28c and 28d were obtained from reactions of benzamido-benzenesulfonamide with four isothiocyanates. Three novel pyrrolidino benzenesulfonylthiourea 33a, 33b and 33c were obtained from the reactions of pyrrolidino benzenesulfonamide with three isothiocyanates. Five acetamido-benzenesulfonylthioureas 26a-26k were obtained from reactions of acetamido-benzenesulfonamide with four different isothiocyanates. All synthesized compounds were successfully characterized by 1H NMR, 13C NMR, DEPT 135, mass spectrometry and melting points.
Benzenesulfonamides 25a-25e, 32, and 27, benzenesulfonylthioureas 28a-28d, 33c, 26a-26e were subjected to in-vitro cyctotoxicity screening against Caco2 cells at concentration of 100 μM and were found to be non-toxic against Caco2 cells. These compounds were then subjected to in-vitro α-glucosidase inhibition study at concentrations of 10 μM, 50 μM, 100 μM and 200 μM. 4-(2-Morpholine-acetamido)-benzenesulfonamide 25-e showed the most promising α-glucosidase inhibition with 95% inhibition at concentration of 50 μM and 98 % inhibition at concentration of 100 μM. Compounds 28-c, 26-b, 26-c and 26-d showed significant improved α-glucosidase inhibition at 200 μM concentration with percent inhibition ranging between 50% and 81%. The study revealed that both sulfonamides and sulfonylthiourea can potentially be used as anti-diabetic agents.&#xd;
DA  - 2026-05-19&#xd;
DB  - ResearchSpace&#xd;
DP  - Univen&#xd;
KW  - Anti-diabetes&#xd;
KW  - In-vitro cytotoxicity&#xd;
KW  - In-vitro a-glucosidase inhibition&#xd;
KW  - Sulfonamides&#xd;
KW  - Sulfonylthioreas&#xd;
LK  - https://univendspace.univen.ac.za&#xd;
PY  - 2026&#xd;
T1  - Synthesis of sulfonylthioureas as anti-diabetic drugs&#xd;
TI  - Synthesis of sulfonylthioureas as anti-diabetic drugs&#xd;
UR  - &#xd;
ER  - &#xd;
</dim:field>
   <dim:field mdschema="dc" element="description">M.Sc. in Chemistry</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">This dissertation discussed the synthesis, cytotoxicity and alpha-glucosidase inhibition of sulfonamides and novel sulfonylthiourea compounds. Three series of novel sulfonylthiourea [benzamido-benzenesulfonylthiourea (28a-28d), pyrrolidino-benzenesulfonylthiourea (33a-33c) and acetamido-benzenesulfonylthiourea (26a-26k) were successfully synthesized in moderate yields to excellent yields. Four novel benzamido-benzenesulfonylthiourea 28a, 28b, 28c and 28d were obtained from reactions of benzamido-benzenesulfonamide with four isothiocyanates. Three novel pyrrolidino benzenesulfonylthiourea 33a, 33b and 33c were obtained from the reactions of pyrrolidino benzenesulfonamide with three isothiocyanates. Five acetamido-benzenesulfonylthioureas 26a-26k were obtained from reactions of acetamido-benzenesulfonamide with four different isothiocyanates. All synthesized compounds were successfully characterized by 1H NMR, 13C NMR, DEPT 135, mass spectrometry and melting points.
Benzenesulfonamides 25a-25e, 32, and 27, benzenesulfonylthioureas 28a-28d, 33c, 26a-26e were subjected to in-vitro cyctotoxicity screening against Caco2 cells at concentration of 100 μM and were found to be non-toxic against Caco2 cells. These compounds were then subjected to in-vitro α-glucosidase inhibition study at concentrations of 10 μM, 50 μM, 100 μM and 200 μM. 4-(2-Morpholine-acetamido)-benzenesulfonamide 25-e showed the most promising α-glucosidase inhibition with 95% inhibition at concentration of 50 μM and 98 % inhibition at concentration of 100 μM. Compounds 28-c, 26-b, 26-c and 26-d showed significant improved α-glucosidase inhibition at 200 μM concentration with percent inhibition ranging between 50% and 81%. The study revealed that both sulfonamides and sulfonylthiourea can potentially be used as anti-diabetic agents.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="sponsorship">National Research Foundation (NRF), Sasol Inzalo Foundation and University of Venda</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="subject">Anti-diabetes</dim:field>
   <dim:field mdschema="dc" element="subject">In-vitro cytotoxicity</dim:field>
   <dim:field mdschema="dc" element="subject">In-vitro a-glucosidase inhibition</dim:field>
   <dim:field mdschema="dc" element="subject">Sulfonamides</dim:field>
   <dim:field mdschema="dc" element="subject">Sulfonylthioreas</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_ZA">UCTD</dim:field>
   <dim:field mdschema="dc" element="title">Synthesis of sulfonylthioureas as anti-diabetic drugs</dim:field>
   <dim:field mdschema="dc" element="type">Dissertation</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>